The Drug-Induced Cardiotoxicity Website and App
Frequency - Incidence
Incidence of cardiac adverse event(s) due to the specific drug as assessed by number of reported/published cases in the literature. Red digits in stars indicate: 0 = Very rare, questionable signal · 1 = < 10 cases · 2 = 10-50 cases · 3 = 50–100 cases · 4 = 100-200 cases · 5 = >200 cases
Evidence level/grade
Evidence level for cardiac adverse event(s) due to the specific drug as estimated using Hill’s (1965), Naranjo’s (1981), and Bégaud’s (1985) criteria applied to published cases. Blue digits in stars indicate: 0 = Questionable · 1 = Low · 2 = Moderate · 3 = Robust · 4 = Definite · 5 = Unquestionable, pathognomonic
Pulmonary edema, noncardiogenic (NCPE)
Publications
Amphotericin B Associated Pulmonary Complications in Chronic Granulomatous Disease Patients.
Pediatric blood & cancer. 2016;63(10):1871-2
Pulmonary reactions during treatment with amphotericin B: review of published cases and guidelines for management.
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America. 2001;33(7):E75-82
Safety and toxicity of amphotericin B in glucose 5% or intralipid 20% in neutropenic patients with pneumonia or fever of unknown origin: randomised study.
BMJ (Clinical research ed.). 1998;317(7155):379-84
Life-threatening adverse event after amphotericin B lipid complex treatment in a patient treated previously with amphotericin B deoxycholate.
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America. 1998;26(4):1016
Cardiopulmonary toxicity after liposomal amphotericin B infusion.
Annals of internal medicine. 1991;114(8):664-6